Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of EPO in the circulation increases and this leads to increased production of red blood cells.
Published March 12, 2025 · Recall initiated: February 3, 2025
Summary
FDA records medical device Class II recall Z-1249-2025, published March 12, 2025 and initiated February 3, 2025. Recalling firm: Beckman Coulter, Inc.; Status: Ongoing; Reported quantity: 498 US; 1576 OUS; Lot: Catalog A16364 UDI-DI 15099590201838 Lot 439363. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Beckman Coulter, Inc.
- Distributor
- Domestic distribution to AL AR AZ CA CT FL ID IL IN KS MA MI NC NE NJ NY OH OR PA TN TX UT WA WV. International distribution to Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Italy, Japan, Korea, Republic of, Netherlands, Philippines, Russian Federation, Saudi Arabia, Slovakia, Spain, United Kingdom of Great Britain and Northern Ireland
- Lot
- Catalog A16364 UDI-DI 15099590201838 Lot 439363
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAROTOR ASSY-SW40, Reference Number 331302, when the rotors are installed in the following centrifuges: OptimaOctober 28, 2026
- FDAROTOR ASSY-SW41, Reference Number 331362, when the rotors are installed in the following centrifuges: OptimaOctober 28, 2026
- FDAIQ200 SPRINT, REF: 700-3322,700-3322RFB, 700-3325, 700-3326, B48997; IQ200 SELECT, REF: 700-3340, 700-3345,October 21, 2026
- FDADxU 840m Iris, REF: C76947; DxU 850m Iris, REF: C49513October 21, 2026
- FDAMedtronic Pipeline Vantage Embolization Device with Shield Technology, REF: PED3-021-350-16, PED3-021-250-14,March 12, 2025
- FDABrand Name: TBS Osteo Product Name: TBS iNsight Model/Catalog Number: TBS iNsight v3.x / pn: OS-TBSi SoftwareMarch 12, 2025
Questions about this recall
Was Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of EPO in the circulation increases and this leads to increased production of red blood cells. recalled?
Yes. FDA published recall Z-1249-2025 on March 12, 2025. Reported hazard: Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit